Results 61 to 70 of about 1,501,016 (387)

Placebo Responses and Placebo Effects in Functional Gastrointestinal Disorders

Frontiers in Psychiatry, 2020
Much has been written about the placebo effects in functional gastrointestinal disorders (FGD), especially in irritable bowel syndrome (IBS), driven by the early hypothesis that in randomized controlled trials (RCTs) of IBS, the placebo effect might be ...
Paul Enck, Sibylle Klosterhalfen
doaj   +1 more source

A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. [PDF]

, 2019
Primary biliary cholangitis (PBC) is typically associated with elevated serum bile acid levels and pruritus, but pruritus is often refractory to treatment with existing therapies.
Apostol, George, Bacon, Bruce, Bowlus, Christopher L, Dorenbaum, Alejandro, Gu, Joan, Hirschfield, Gideon M, Jones, David, Kennedy, Ciara, Levy, Cynthia, Luketic, Velimir, Mayo, Marlyn J, Medendorp, Sharon, Novak, Patricia, Patanwala, Imran, Pockros, Paul J, Vuppalanchi, Raj   +15 more
core   +2 more sources

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2016
IMPORTANCE Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor.
P. Miller, G. Hattersley, B. Riis, Gregory C. Williams, E. Lau, L. A. Russo, P. Alexandersen, C. Zerbini, Ming‐yi Hu, A. Harris, L. Fitzpatrick, F. Cosman, C. Christiansen   +12 more
semanticscholar   +1 more source

Beyond p‐values: Assessing clinical significance in acupuncture research

Advanced Chinese Medicine, EarlyView.
Abstract In acupuncture randomized controlled trials (RCTs), the proper interpretation of results requires a thorough understanding of key statistical concepts such as p‐value, effect size, and the minimal clinically important difference (MCID). This paper explores the relationships among these metrics and their implications for assessing the clinical ...
Changzhen Gong
wiley   +1 more source

Ustekinumab treatment and improvement of physical function and health‐related quality of life in patients with psoriatic arthritis [PDF]

, 2016
Objective: Examine ustekinumab effects on patient-reported outcomes (PROs) in PSUMMIT-1/PSUMMIT-2 patients with active psoriatic arthritis (PsA) who were methotrexate (MTX)-naïve, MTX-experienced, or anti-tumor necrosis factor (TNF)-experienced ...
Dalal, Ekelund, Feldman, Finlay, Fries, Gupta, Husted, Husted, Kavanaugh, Kimball, Koo, McInnes, Mease, Puig, Ritchlin, Schünemann, Tillett, Walsh, Ware   +18 more
core   +1 more source

Placebo by proxy

BMJ, 2011
Clinicians’ and family members’ feelings and perceptions about a treatment may influence their judgments about its ...
David J. Grelotti, Ted J. Kaptchuk
openaire   +4 more sources

3D MRI Tract‐Specific Spinal Cord Lesion Pattern Improves Prediction of Distinct Neurological Recovery

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To distinguish lateralized motor‐ and sensory‐tract damage after acute spinal cord injury (SCI) and explore its predictive power for motor and sensory recovery. Methods Thirty‐five SCI patients (two female) from a multi‐center data set (placebo‐arm of the Nogo‐A‐Inhibition in SCI trial) underwent routine T2‐weighted sagittal MRI ...
Lynn Farner, Tim M. Emmenegger, Simon Schading‐Sassenhausen, Julia Berroth, Maryam Seif, Armin Curt, Patrick Freund, The Nogo Inhibition in Spinal Cord Injury Study Group   +7 more
wiley   +1 more source

Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial

Efficacy and Mechanism Evaluation, 2015
Background: Diarrhoea-predominant irritable bowel syndrome (IBS-D) is a common outcome after inflammation due to bacterial gastroenteritis. Several studies have shown ongoing immune activation in the mucosa of patients with IBS-D and a number of studies ...
Ching Lam, Wei Tan, Matthew Leighton, Margaret Hastings, Melanie Lingaya, Yirga Falcone, Xiaoying Zhou, Luting Xu, Peter Whorwell, Andrew F Walls, Abed Zaitoun, Alan Montgomery, Robin C Spiller   +12 more
doaj   +1 more source

The Comparative Effectiveness and Tolerability of Sphingosine‐1‐Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta‐Analysis of Randomized Controlled Trials

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory effects, such as preventing the formation of new CNS lesions and the reactivation of pre ...
Faizan Shahzad, Taimoon Rasheed, Momina Riaz Siddiqui, Hamza Hamid, Marwah Bintay Khalid, Haroon Shabbir, Besher Shami, Abdullah, Syed Ijlal Ahmed   +8 more
wiley   +1 more source

AVURT: aspirin versus placebo for the treatment of venous leg ulcers – a Phase II pilot randomised controlled trial

Health Technology Assessment, 2018
Background: Venous leg ulcers (VLUs) are the most common cause of leg ulceration, affecting 1 in 100 adults. VLUs may take many months to heal (25% fail to heal). Estimated prevalence is between 1% and 3% of the elderly population.
Helen Tilbrook, Laura Clark, Liz Cook, Martin Bland, Hannah Buckley, Ian Chetter, Jo Dumville, Chris Fenner, Rachael Forsythe, Rhian Gabe, Keith Harding, Alison Layton, Ellie Lindsay, Catriona McDaid, Christine Moffatt, Debbie Rolfe, Illary Sbizzera, Gerard Stansby, David Torgerson, Peter Vowden, Laurie Williams, Robert Hinchliffe   +21 more
doaj   +1 more source